Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$14.9 million.

  • CytomX Therapeutics' Net Cash Flow fell 48008.59% to -$14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year decrease of 14358.2%. This contributed to the annual value of $21.0 million for FY2024, which is 11189.43% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Net Cash Flow of -$14.9 million as of Q3 2025, which was down 48008.59% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Net Cash Flow peaked at $137.8 million during Q1 2021, and registered a low of -$137.3 million during Q1 2023.
  • For the 5-year period, CytomX Therapeutics' Net Cash Flow averaged around -$8.3 million, with its median value being -$8.9 million (2023).
  • Per our database at Business Quant, CytomX Therapeutics' Net Cash Flow skyrocketed by 49898.22% in 2024 and then tumbled by 48008.59% in 2025.
  • Over the past 5 years, CytomX Therapeutics' Net Cash Flow (Quarter) stood at -$30.8 million in 2021, then skyrocketed by 420.66% to $98.6 million in 2022, then tumbled by 108.98% to -$8.9 million in 2023, then skyrocketed by 71.49% to -$2.5 million in 2024, then crashed by 488.59% to -$14.9 million in 2025.
  • Its last three reported values are -$14.9 million in Q3 2025, $1.4 million for Q2 2025, and $9.6 million during Q1 2025.